PIK3CA and neoplasm: Cell lines with PIK3CA amplification was positively associated with BYL719 sensitivity (P=0.0037) and tumor-bearing mice with PIK3CA amplification responded to BYL719, leading to a response rate of −18% (lung cancer) and −80% (gastric cancer).